Fact Sheet: Innovation 2022

SECOND OPINION: DEBUNKING BIG PHARMA’S BOGUS INNOVATION RHETORIC Brand Name Drug Companies Claim Lowering Rx Prices Will Undercut R&D — The Facts Disagree For far too long Big Pharma has used the excuse that research and development (R&D) costs justify out-of-control prescription drug prices and that solutions to lower prices threaten innovation into new breakthroughs.

Fact Sheet: Morning Consult Prescription Drug Pricing Poll

AMERICANS FACE FINANCIAL CHALLENGES AS A RESULT OF INCREASING DRUG PRICES More than one in four American voters reported (26%) that they or a family member had 26% financial difficulty affording a prescribed medication in the last 12 months. VOTERS OVERWHELMINGLY WANT CONGRESS TO ACT LACK OF ACTION WILL IMPACT VOTE IN NEXT ELECTION Four

Fact Sheet: Cancer Drug Prices

THE PROBLEM: A CRISIS OF AFFORDABILITY The out-of-control prices set by Big Pharma on prescription drugs used to treat cancer have created a crisis of affordability — and placed breakthrough treatments out-of-reach for too many American patients. Patients and families should never have to face heart-wrenching choices between paying for their cancer treatment or for

Drug Pricing Overview – 117th Congress

Fact Sheet: OUT-OF-CONTROL DRUG PRICES AN URGENT CONCERN FOR AMERICAN FAMILIES

Ninety-six percent of voters agree lowering drug prices is an important challenge facing Americans. Seventy-one percent say lowering drug prices is “very important.”

Fact Sheet: Patent Abuse

Prescription drug prices are out-of-control thanks to the anti-competitive tactics and price-gouging practices of Big Pharma. Despite an escalating crisis of affordability, made worse by the economic impact of the COVID-19 pandemic, brand name drug companies continue to engage in anti-competitive behavior and price-gouging tactics in order to keep prices high and pad their bottom

Fact Sheet: Oversight Hearings

AN OPPORTUNITY TO HOLD BIG PHARMA ACCOUNTABLE The U.S. House of Representatives Committee on Oversight and Reform is scheduled to hold two days of hearings with Big Pharma executives on September 30 and October 1. Executives for brand name drug giants including Bristol Myers Squibb/Celgene, Amgen and Novartis are slated to testify. Lawmakers must use

Fact Sheet: No Price Hikes

Prescription drug prices are out-of-control. Too many Americans were already unable to afford their medications and resorting to dangerous measures like rationing — before the historic economic uncertainty of the current crisis. It is critical patients are able to take their medications as prescribed in order to stay healthy. Now is not the time for

Fact Sheet: KEEP YOUR PROMISE: CONGRESS MUST ACT TO HOLD BIG PHARMA ACCOUNTABLE, LOWER DRUG PRICES

THE CRISIS OF RISING PRESCRIPTION DRUG PRICES: The anti-competitive tactics and price-gouging practices of Big Pharma have created a crisis of prescription drug affordability in America. Today, as many as one-in-four Americans are unable to afford their medications. Despite the mounting crisis, brand name drug makers continue increasing prices and fighting to evade responsibility. Big

Document: CSRxP Letter to Senate Finance Committee

The Campaign for Sustainable Rx Pricing (CSRxP) wishes to commend you for your strong bipartisan efforts to lower prescription drug prices for Americans by moving forward with the U.S. Senate Committee on Finance package on drug pricing. CSRxP believes that the Senate Finance package is a good first step in slowing the unsustainable growth in

Document: Restructuring the CMS Federal Reinsurance Program to Include Manufacturer Liability

As prescription drug prices continue to rise, many stakeholders have debated how to slow the trend and who should pay for it. The Medicare Advantage and Part D programs remain at the center of this discussion. Organizations such as the Medicare Payment Advisory Commission (“MedPAC”) and the American Action Form (“AAF”) as well as Congress

Document: USMCA Letter

The Campaign for Sustainable Rx Pricing (CSRxP) is a broad-based coalition of leaders – physicians, nurses, hospitals, consumers, health plans, PBMs, pharmacists and businesses — promoting bipartisan, market-based solutions to lower drug prices in America. We appreciate the bipartisan attention and activity that lawmakers in Congress have placed on tackling the crisis of rising prescription

Fact Sheet: Big Pharma: Investing Boldly in Advertising and Profits, Not R&D

Drug prices are out of control. But Big Pharma is posting record profits. Where is all that money going? Not research and development. For the top ten U.S. companies, nearly 80% of every Big Pharma dollar goes to something other than R&D.¹

Final Comment Letter: Proposed Rebate Rule

Despite efforts from the brand drug industry to suggest otherwise, brand pharmaceutical companies – and pharmaceutical companies alone – are the drivers of the high drug prices American consumers and taxpayers face every day. Brand manufacturers set unsustainably high launch prices for their products and typically increase those prices at rates that far exceed inflation…

Drug Pricing Overview: 116th Congress

On behalf of the Campaign for Sustainable Rx Pricing (CSRxP), a nonpartisan coalition of doctors, physicians, nurses, hospitals, consumers, health plans, PBMs, pharmacists, patient advocates and businesses committed to lowering drug prices, congratulations on being elected to represent your constituents in the 116th Congress. Our organization believes no one should ever have to choose between

Fact Sheet: The Facts About Rising Drug Prices

Drug prices in the United States are too high and continue to skyrocket. The unsustainable cost of prescription drugs not only puts pressure on the health care system but increasingly; patients, employers, and providers are paying prices that are too high.

Fact Sheet: Proposals for Change – Detailed

The current market for pricing drugs in the United States is broken, and it’s unsustainable for American businesses, families, and our economy. Today, prescription drug expenditures make up nearly 20 percent of all health care costs, and prescription spending is growing faster than any other part of the health care dollar.

Fact Sheet: CSRxP Proposals for Change – Summary

Drug prices in the United States are too high and sharply rising prescription drug prices threaten the affordability of health care and the vitality of our entire economy. CSRxP has developed market-based reforms that restore a functioning market by increasing transparency, promoting competition and innovation, and that result in value.

Document: CSRxP Comment Letter – CMS-4187-P

Dear Administrator Verma: The Campaign for Sustainable Rx Pricing (CSRxP) is a nonpartisan coalition of organizations committed to fostering an informed discussion on sustainable drug pricing and developing bipartisan, market-based solutions that promote competition, transparency, and value to improve affordability while maintaining patient access to innovative prescription drugs that can improve health outcomes and save

Document: Coalition Letter on BBA Donut Hole

Dear Leader McConnell, Leader Schumer, Speaker Ryan and Leader Pelosi: We are writing to urge you to preserve the actions Congress took in the Bipartisan Budget Act of 2018 (BBA) to protect seniors and taxpayers from out-of-control drug prices as you embark on the lame duck session of Congress. Over the past five years, drug

Document: Coalition Letter Opposing Donut Hole Change

Dear Leader McConnell, Leader Schumer, Speaker Ryan and Leader Pelosi: We are writing to urge you to preserve the actions Congress took in the Bipartisan Budget Act (BBA) of 2018 to protect seniors and taxpayers from out-of-control drug prices. Over the past five years, drug manufacturers have increased the prices of brand name drugs at

Document: CSRxP Letter of Support for DTC Provision in Labor-HHS 8.27.18

Dear Chairman Frelinghuysen, Ranking Member Lowey, Chairman Cole, and Ranking Member DeLauro: The Campaign for Sustainable Rx Pricing (CSRxP) is writing to encourage you to maintain the Senate’s inclusion of a provision in the final Labor-HHS Appropriations bill to provide funding to enable the U.S. Department of Health and Human Services (HHS) to require disclosure

Document: Interchangeability Letter to FDA

Dear Commissioner Gottlieb: We appreciate the Food and Drug Administration’s (FDA) recent actions regarding biosimilars – specifically the FDA’s Biosimilars Action Plan. As you know, one of the most important ways the FDA can help increase marketplace competition is by finalizing its guidance, “Considerations in Demonstrating Interchangeability With a Reference Product” regarding the process a

Document: CSRxP Comments on Drug Price Blueprint

Dear Secretary Azar: The Campaign for Sustainable Rx Pricing (CSRxP) is a nonpartisan coalition of organizations committed to fostering an informed discussion on sustainable drug pricing and to developing bipartisan, market-based solutions that promote competition, transparency, and value to improve affordability while maintaining patient access to innovative prescription drugs. Our members represent organizations including consumers,

Fact Sheet: CSRxP Response to HHS Prescription Drug Pricing Blueprint Executive Summary

Consumers currently spend 23 cents of every health care dollar on prescription drugs – an amount that can and must come down, as needlessly high drug prices and out-of-pocket spending threaten the financial security, health and well-being of American patients and their families, as well as strain Federal and State budgets.1 As such, CSRxP welcomes

Document: CSRxP Testimony – Senate Finance Committee Hearing on

Testimony Submitted for the Record U.S. Senate Finance Committee Hearing: “Prescription Drug Affordability and Innovation: Addressing Challenges in Today’s Market” – Chairman Hatch, Ranking Member Wyden, and members of the Senate Finance Committee, the Campaign for Sustainable Rx Pricing (CSRxP) thanks you for the opportunity to submit testimony for the record on the critically important

Document: Coalition Letter on CREATES Act

Dear Chairman Grassley and Ranking Member Feinstein: We, the undersigned, commend you for your leadership and commitment to reducing out-of-control prescription drug prices and stopping anti-competitive abuses that keep drug prices high. We are encouraged that the Senate Judiciary Committee has noticed a markup of the Creating and Restoring Equal Access to Equivalent Samples (CREATES)